These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23826163)

  • 1. Determination of the human antibody response to the neutralization epitopes encompassing amino acids 313-327 and 432-443 of hepatitis C virus E1E2 glycoproteins.
    Liu R; Rao H; Wang J; Xie X; Jiang D; Pan X; Zhao P; Zhang H; Wei L
    PLoS One; 2013; 8(6):e66872. PubMed ID: 23826163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus.
    Ahsan A; Dar S; Hassan F; Ghafoor F; Yousuf MH; Shahzad-Ul-Hussan S
    PLoS One; 2021; 16(8):e0256816. PubMed ID: 34449828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.
    Keck ZY; Xia J; Wang Y; Wang W; Krey T; Prentoe J; Carlsen T; Li AY; Patel AH; Lemon SM; Bukh J; Rey FA; Foung SK
    PLoS Pathog; 2012; 8(4):e1002653. PubMed ID: 22511875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
    Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
    J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
    Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
    PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus.
    Johansson DX; Voisset C; Tarr AW; Aung M; Ball JK; Dubuisson J; Persson MA
    Proc Natl Acad Sci U S A; 2007 Oct; 104(41):16269-74. PubMed ID: 17911260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
    Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
    J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
    Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
    J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.
    Keck ZY; Pierce BG; Lau P; Lu J; Wang Y; Underwood A; Bull RA; Prentoe J; Velázquez-Moctezuma R; Walker MR; Luciani F; Guest JD; Fauvelle C; Baumert TF; Bukh J; Lloyd AR; Foung SKH
    PLoS Pathog; 2019 May; 15(5):e1007772. PubMed ID: 31100098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies.
    Stamataki Z; Coates S; Evans MJ; Wininger M; Crawford K; Dong C; Fong YL; Chien D; Abrignani S; Balfe P; Rice CM; McKeating JA; Houghton M
    Vaccine; 2007 Nov; 25(45):7773-84. PubMed ID: 17919789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.
    Ruwona TB; Giang E; Nieusma T; Law M
    J Virol; 2014 Sep; 88(18):10459-71. PubMed ID: 24965471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles.
    Kachko A; Kochneva G; Sivolobova G; Grazhdantseva A; Lupan T; Zubkova I; Wells F; Merchlinsky M; Williams O; Watanabe H; Ivanova A; Shvalov A; Loktev V; Netesov S; Major ME
    Vaccine; 2011 Dec; 30(1):69-77. PubMed ID: 22041300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.
    Tarr AW; Urbanowicz RA; Hamed MR; Albecka A; McClure CP; Brown RJ; Irving WL; Dubuisson J; Ball JK
    J Virol; 2011 May; 85(9):4246-57. PubMed ID: 21325403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.
    Rafique S; Idrees M; Ali A; Iqbal M
    Mol Biol Rep; 2014 Jun; 41(6):3945-50. PubMed ID: 24566682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation of human monoclonal antibodies to the envelope e2 protein of hepatitis C virus and their characterization.
    Shimizu YK; Hijikata M; Oshima M; Shimizu K; Alter HJ; Purcell RH; Yoshikura H; Hotta H
    PLoS One; 2013; 8(2):e55874. PubMed ID: 23409074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2.
    El Abd YS; Tabll AA; El Din NG; Hosny Ael-D; Moustafa RI; El-Shenawy R; Atef K; El-Awady MK
    Virol J; 2011 Aug; 8():391. PubMed ID: 21819575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Flag-tagged E1E2 glycoproteins from three hepatitis C virus genotypes are biologically functional and elicit cross-reactive neutralizing antibodies in mice.
    Krapchev VB; Rychłowska M; Chmielewska A; Zimmer K; Patel AH; Bieńkowska-Szewczyk K
    Virology; 2018 Jun; 519():33-41. PubMed ID: 29631174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity.
    Zhang P; Zhong L; Struble EB; Watanabe H; Kachko A; Mihalik K; Virata ML; Alter HJ; Feinstone S; Major M
    Proc Natl Acad Sci U S A; 2009 May; 106(18):7537-41. PubMed ID: 19380744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.
    Tarr AW; Owsianka AM; Jayaraj D; Brown RJP; Hickling TP; Irving WL; Patel AH; Ball JK
    J Gen Virol; 2007 Nov; 88(Pt 11):2991-3001. PubMed ID: 17947521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes.
    Mancini N; Diotti RA; Perotti M; Sautto G; Clementi N; Nitti G; Patel AH; Ball JK; Clementi M; Burioni R
    PLoS One; 2009 Dec; 4(12):e8254. PubMed ID: 20011511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.